AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01774461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
Study NCT00429936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenretinide
Description: Once daily 30 minutes after the evening meal for 24 months
Study NCT00429936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenretinide
Description: Once daily 30 minutes after the evening meal for 24 months
Study NCT00796952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: focused attention sessions
Description: Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period.
Study NCT00796952 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Valchuff
Description: Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment.
Study NCT00796952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharyngocise
Description: Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
Study NCT06429228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter removal after surgery
Description: Removal of catheter placed during the procedure in first or second post-surgical days.
Study NCT00409968 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Biopsy
Description: A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
Study NCT02297178 — intervention group
Intervention type: PROCEDURE
Intervention: Cystoscopy only
Description: Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
Study NCT02297178 — intervention group
Intervention type: PROCEDURE
Intervention: Cystoscopy and Urethral dilatation
Description: Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
Study NCT02411058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninformed
Description: Users will receive 20x their usual incentives for two weeks, but will either receive no emails informing them about the incentive program.
Study NCT04261660 — intervention group
Intervention type: OTHER
Intervention: NO intervention
Description: NO INTERVENTION
Study NCT04446715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufentanil
Description: Patients will receive sufentanil in spinal anesthesia
Study NCT04446715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meperidine
Description: Patients will receive meperidine in spinal anesthesia
Study NCT02411058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed
Description: Users will receive 20x their usual incentives for two weeks, and they will receive emails informing them about the incentives (one announcement before the incentives begin, and one email every two days reminding them about the overall incentive program). These emails will contain information about the incentives and the purpose of the incentives. The reminder emails sent every two days, however, will include more information about the overall program incentives to maximize the number of participants who learn about the incentive program at some point.
Study NCT04446715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Patients will receive 0.5% heavy bupivacaine in spinal anesthesia
Study NCT00477906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-Vax- autologous, hapten-modified melanoma vaccine
Description: Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
Study NCT00477906 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: M-Vax- autologous, hapten-modified melanoma vaccine
Description: Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
Study NCT02145078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT02145078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT02145078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT02145078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04570995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week
Study NCT04570995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower Oil
Description: Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week
Study NCT01974505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intubation using optiscope
Description: Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
Study NCT01286220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dilute bleach baths
Description: Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
Study NCT01286220 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
Study NCT02674490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-tDCS (1 mA)
Description: 1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
Study NCT02674490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SALT
Description: Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
Study NCT02674490 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: SALT
Description: Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
Study NCT02674490 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
Study NCT00750282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben (BAY94-9172)
Description: Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
Study NCT03942913 — intervention group
Intervention type: OTHER
Intervention: an observational study
Description: this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
Study NCT03471390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ProQuaS 2 Intervention
Description: Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
Study NCT00389181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interventional therapy
Description: All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
Study NCT00389181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
Study NCT00389181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical management
Description: Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
Study NCT04219618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Off-Pump
Description: After a standard median sternotomy, pericardium will be divided to expose the heart and major vessels, and the aortic cannulation sutures will be placed. Pyramid positioner will be applied to the apex of the heart, and the heart will be manually elevated upward. The inflow cannula placement location and placement of the sewing ring will be done with pledged sutures. The LV diaphragmatic site coring will be completed, and immediate LV digital exploration will be accomplished. The LVAD inflow cannula will be inserted through the sewing ring into the LV cavity. Upon completing proper LVAD inflow cannula placement into the LV and securing it in position, the heart will be dropped into the pericardial cavity with the outflow graft elevated for LVAD and outflow graft de-airing and to prevent potential later air embolization. A partial occlusion clamp will be placed on the ascending aorta and appropriately trimmed outflow graft will be sewn to the aorta.
Study NCT04219618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-Pump
Description: A standard median sternotomy incision will be performed and pericardium divided to expose the heart and major vessels. Cannulation will be done through the aorta and the right atrium and the patient will be put on cardiopulmonary bypass (CPB). The patient's heart will be freed from the surrounding tissues. With a cylindrical blade, the surgeon will excise a core of myocardium from the apex. The LVAD sewing ring will then be sutured to the margins of the apical hole. The LVAD will be inserted into the LV cavity through the sewing ring. The outflow graft will be measured for the anastomosis into the aortic root. Partial occlusion clamp will be placed on the aortic root and the anastomosis will be performed. De-airing will be performed and the LVAD will be started. The patient will then be weaned from CPB and decannulated.
Study NCT00539643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bead Block microspheres
Description: Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
Study NCT00539643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bead + Dox Arm
Description: Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
Study NCT03304860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
Study NCT01282671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months. A Positive expiratory pressure (PEP) device PEP ventil, System 22 (Rium Medical, Täby, Sweden) is used to create an expiratory resistance of +10 cm H2O.
Study NCT01740102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
Study NCT04204213 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tai Chi Exercise
Description: 8 Section Brocade (Baduanjin) sitting Tai Chi classes + Healthcare Education seminars
Study NCT03149016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy-assisted Retraction
Description: Using a tunneling technique, the researcher will perform the intervention in the alveolar bone surrounding the upper incisors before retraction.
Study NCT02585596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537 1000mg/day
Description: YH23537 500mg 2 tab
Study NCT02585596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537 2000mg/day
Description: YH23537 500mg 4 tab
Study NCT02585596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537 3000mg/day
Description: YH23537 500mg 6 tab
Study NCT01931995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS positively correlated DLPFC
Description: TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
Study NCT01931995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMS to negatively correlated DLPFC
Description: TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
Study NCT00964990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
Study NCT00964990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
Study NCT02586519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurroSense Rx System
Description: The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur.
Study NCT02586519 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SurroSense Rx System
Description: The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur.
Study NCT01901653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (SC16LD6.5)
Study NCT02228239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
Study NCT02228239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.
Study NCT02228239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Esketamine)
Description: Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
Study NCT02585596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: YH23537 500mg tab placebo
Study NCT02585596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: YH23537 500mg tab placebo
Study NCT00301080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Study NCT00301080 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04323228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement enriched in antioxidants
Description: the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.
Study NCT04323228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cellulose-containing placebo capsules
Description: The placebo group will receive an oral supplement at the same time in the same shape/size/color.
Study NCT02761655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Strategies
Description: Memory strategies on encoding retention, retrieval, execution and monitoring
Study NCT03347175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volume controlled ventilation
Description: Volume controlled ventilation mode
Study NCT03347175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure controlled ventilation
Description: Pressure controlled ventilation
Study NCT03347175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP mode
Description: CPAP mode only
Study NCT03324659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Meditation
Description: The Exercise and Meditation group will listen to recorded meditations (15 minutes) that are based on mindfulness. They will then walk on a treadmill for 30 minutes at a moderate intensity. The intervention is completed five days per week for four weeks.
Study NCT03324659 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The Control group will listen to a recorded audio book for 15 minutes, They will then sit quietly for 30 minutes. The intervention is completed five days per week for four weeks.
Study NCT02810314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological battery
Description: neuropsychological battery including cognitive and behavioural tests
Study NCT02810314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resting state functional magnetic resonance image (rs-fMRI)
Description: rs-fMRI
Study NCT02810314 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: resting state functional magnetic resonance image (rs-fMRI)
Description: rs-fMRI
Study NCT03036501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-Risdiplam
Description: \[\^14C\]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries \[μCi\]) of \[14C\]-labeled Risdiplam.